Protein / target
Small ribosomal subunit protein bS1
Protein at a glance
Biological role
Structural constituent of ribosome
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Required for translation of most natural mRNAs except for leaderless mRNA (PubMed:12068815, PubMed:17376482, PubMed:24339747, PubMed:7003157, PubMed:9677288). Binds mRNA upstream of the Shine-Dalgarno (SD) sequence and helps it bind to the 30S ribosomal subunit; acts as an RNA chaperone to unfold structured mRNA on the ribosome but is not essential for mRNAs with strong SDs and little 5'-UTR structure, thus it may help fine-tune which mRNAs that are translated (PubMed:24339747). Unwinds dsRNA by binding to transiently formed ssRNA regions; binds about 10 nucleotides (PubMed:22908248). Has a preference for polypyrimidine tracts (PubMed:778845). Negatively autoregulates its own translation (PubMed:2120211)
Subcellular location
Domains and Gene Ontology detail (18)Hide
Domains & features
Gene Ontology
- Ccytoplasm
- Ccytosolic small ribosomal subunit
- Cmembrane
- FmRNA binding
- FRNA binding
- Fsingle-stranded RNA binding
- Fstructural constituent of ribosome
- Pcytoplasmic translation
- Pnegative regulation of cytoplasmic translation
- Ppositive regulation of cytoplasmic translation
- Pribosomal small subunit assembly
- Ptranslation
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
Bacterial 70S ribosome inhibitor
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 8 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Industry developmentFe-doped BiVO4/g-C3N4 heterojunction for efficient tetracycline degradation under low-intensity UV irradiation
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA207757)
- New publicationImpact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.
- New publicationGuidelines of care for the management of acne vulgaris.
- New publicationNew Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
- Safety communication
Drug Safety Update: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- Safety communication
Drug Safety Update: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- New publicationRisk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
- Label change
Label change: DOXYCYCLINE (ANDA207757)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.